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Abstract
Background: The exploitation of the surface display system of food and commensal lactic acid bacteria (LAB) for
bacterial, viral, or protozoan antigen delivery has received strong interest recently. The Generally Regarded as Safe
(GRAS) status of the Lactococcus lactis coupled with a non-recombinant strategy of in-trans surface display, provide
a safe platform for therapeutic drug and vaccine development. However, production of therapeutic proteins fused
with cell-wall anchoring motifs is predominantly limited to prokaryotic expression systems. This presents a major
disadvantage in the surface display system particularly when glycosylation has been recently identified to
significantly enhance epitope presentation. In this study, the glycosylated murine Tyrosinase related protein-2
(TRP-2) with the ability to anchor onto the L. lactis cell wall was produced in suspension adapted Chinese Hamster
Ovary (CHO-S) cells by expressing TRP-2 fused with cell wall anchoring LysM motif (cA) at the C-terminus.
Results: A total amount of 33 μg of partially purified TRP-2-cA from ~6.0 g in wet weight of CHO-S cells was
purified by His-tag affinity chromatography. The purified TRP-2-cA protein was shown to be N-glycosylated and
successfully anchored to the L. lactis cell wall.
Conclusions: Thus cell surface presentation of glycosylated mammalian antigens may now permit development of
novel and inexpensive vaccine platforms.
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Background
Surface display of engineered antigens on the Lactic acid
bacteria (LAB) is currently being investigated as promis-
ing cellular vehicles for vaccine delivery [1–3]. This ap-
proach manipulates the natural cell surface molecular
localisation of proteins that direct fundamental bio-
logical processes such as cell to inter-cell recognition,
signal transduction, surface anchoring, colonisation and
immunological interaction in living organisms [4]. Be-
sides their GRAS (Generally Regarded as Safe) status
compared to their attenuated pathogenic counterparts,
the LAB, with probiotic and immunomodulatory proper-
ties have the ability to survive passage through both ani-
mals and humans for up to 5–7 days [5]. This has made
LAB an excellent candidate for oral and intranasal vac-
cine development [6, 7]. Therefore, LAB such as Lacto-
coccus lactis can be genetically engineered to become an
efficient recombinant cell factory for DNA delivery as
well as production and presentation of antigens [6, 8].
The presentation of antigens through surface display or
secretion by L. lactis in numerous studies utilises the
well understood and characterised surface binding pro-
tein domain such as transmembrane domains, lysin
motif (LysM) and LPXTG motifs [9, 10].
Based on the findings described above, the LAB have
the potential to be developed as a tumour antigen carrier
for therapeutic or prophylactic cancer vaccines. Such
cancer vaccines would be able to mount sustainable
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immune responses to eradicate primary tumours as well
as prevent cancer relapses [11]. Since the early discovery
of probiotic anti-tumour activity [12], the LAB have
been primarily manipulated as prophylactic adjuvants
for prevention of colorectal cancer [13] as well as breast
and bladder cancers, albeit to a lesser extent. However,
the exact mechanism of LAB anti-tumour activity has
not been fully understood. It has been hypothesised that
the competitive inhibition of LAB in the intestinal
microflora may have resulted in disruption of metabolic
equilibrium, digestion of potential carcinogens and pro-
motion of a T helper 1 immune response through muco-
sal immunity [14, 15]. Cancer antigen delivery by the
LAB, on the other hand, has not been widely explored
and is only limited to two examples: 1) surface display of
viral antigens from the human papillomavirus type-16
(HPV-16) E7 antigen on L. lactis, Lactobacillus plan-
tarum and Lactobacillus casei for cervical cancer treat-
ment [6, 16] as well as 2) oncofetal antigen surface
display by L. plantarum [17].
TRP-2 (Tyrosinase related protein-2) is an enzyme
involved in melanin synthesis which undergoes N-
glycosylation and translocates into the melanosome in
melanocytes. It has been reported to be a tumour-
associated antigen present in both melanocytes and
melanoma and as such, TRP-2 has been intensely
studied as a viable therapeutic and prophylactic vaccine
candidate for melanoma and glioblastoma [18, 19]. The
TRP-2 DNA vaccination for glioblastoma multiforme
treatment has resulted in tumour regression and immuno-
logical targeting to increase chemotherapeutic drug sensi-
tivity [19, 20]. Therapeutic effects for melanoma by
alphavirus (Venezuelan equine encephalitis virus, VEE)
replicon [21], cytomegalovirus (CMV) [22], attenuated
Salmonella typhimurium [23] and Listeria monocytogenes
[24] carrying TRP-2 have also been reported. Surprisingly,
despite good documentation of the role of LABs as
adjuvants in mucosal immunogenicity [25, 26], these
GRAS status bacteria have yet to be manipulated to
express TRP-2 for both therapeutic and prophylactic
settings. In addition, common autoimmunity side effects
of hypopigmentation (vitiligo) resulting from TRP-2
(self-antigen) immunization have been observed to be
dependent on the vaccine strategies [21, 27].
In this study, live L. lactis surface displaying post-
translationally modified TRP-2 in trans was developed
with the intention of future use as a prophylactic and
therapeutic cancer vaccine. To date, bacterial surface
display systems for heterologous protein mainly utilize a
recombinant surface display mechanism. However, these
recombinant bacterial surface display systems are very
much limited to non-glycosylated proteins [2, 3, 27, 28]
since prokaryotic cells, which in general do not undergo
post-translational modifications, are used as cell factories
to produce the recombinant proteins fused to the sur-
face display anchor domain. Thus, the recombinant bac-
terial surface display system may not be suitable if
glycosylation is vital for the folding and function of tar-
get proteins [29]. The recent emergence of the in-trans
surface display system [9, 30, 31] provides an attractive
platform for glycoprotein delivery. In the in-trans sys-
tem, the protein of interest is fused with the target
bacteria’s surface anchoring motif (SAM), which is
expressed and purified from a separate host cell be-
fore it is externally introduced to the bacterial cell
wall. This strategy was utilised in this study by pro-
ducing TRP-2-cA glycoprotein fused with lactococcal
cell wall anchor domain in Chinese Hamster Ovary
(CHO) cells before subsequent binding to L. lactis
cell wall. To our knowledge, this is the first report of
prokaryotes surface displaying a glycosylated mamma-
lian protein.
Methods
Bacterial strains and culture conditions
Plasmid construction and cloning was carried out by
utilizing the TOP 10 E. coli strain (Invitrogen, USA).
The TOP 10 E. coli (Invitrogen, USA) was grown in LB
broth by incubating at 37 °C for 12-16 h and shaken at
250 rpm. During positive transformation screening and
maintenance, the TOP 10 E. coli (Invitrogen, USA) strain
was grown in LB agar/broth supplemented with 100 μg/ml
of ampicillin.
Gene amplification and plasmids construction
Both trp-2 1-472 epitope and cA gene DNA template were
codon optimized based on CHO cell codon frequency
table (Codon Usage Database at http://www.kazusa.or.jp/
codon/cgi-bin/showcodon.cgi?species=10029) in reference
to Mus musculus cell-line B16F10 TRP-2 [Accession no:
EU554632.1] and L. lactis N-acetylmuramidase LysM mo-
tifs [Accession no: U17696.1]. However the native murine
TRP-2 signal peptide, mtrp-21-23 was replaced with
Chinese Hamster TRP-2, Cricetulus griseus, TRP-2,
[Accession no: ERE88475.1] signal peptide, chTRP-21-23 to
promote target protein production in CHO-S cells.
Additional linker sequence, 5’-GGCGGCTCCGGCG
GCGGCTCCGGC-3’ which corresponds to GGSGG
GSG amino acid linker sequence was incorporated
upstream to the cA sequence for gene synthesis. Six
histidine repeats with an enterokinase cleavage site
were also incorporated downstream of the aforemen-
tioned codon optimized, synthesized cA sequence.
The trp-2 1-472 epitope was amplified by trp-2 1-472
forward primer, 5’-ATATAAGCTTACCATGGGCCTG
GTGCACTG-3’ and reverse primer, 5’- ATATGGA
TCCGTGGTGGTGGTGGTGGTGGCCGG -3’ contain-
ing HindIII and BamHI restriction sites respectively. The
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cA sequence was amplified by cA forward primer 5’- G
CGCGGATCCGGCGGCTCCGGCGGCGGCTC-3’ and
reverse primer 5’- ATATGCGGCCGCTCAGTGGTGG
TGGTGGTGGTGGCCGGTCC -3’ containing BamHI
and NotI restriction sites. PCR reaction was carried out in
1× Pfu reaction buffer containing 2 mM MgSO4, 0.2 mM
dNTP, 2 units of Pfu polymerase (Fermentas, USA),
0.5 μM of forward and reverse primers and approximately
20 ng of DNA template. The thermal cycler temperature
condition for a 20 cycle amplification was set at a
94 °C /1 min, 62 °C/1 min and 72 °C /2.5 min with a
final extension of 72 °C /10 min. Amplified trp-2 1-472
and cA genes replicates were gel purified by using
Wizard® SV Gel and PCR Clean-Up System (Promega,
USA). Both of the purified genes were then digested
with BamHI at 37 °C for 3 h separately and ligated
using T4 DNA Ligase (Fermentas, USA) at 1:1 gene
ratio overnight at 4 °C. The resulting DNA ligation
mixture was used as a template to amplify trp-2 1-472-cA
fusion gene by using trp-2 1-472 forward primer and cA
reverse primer under abovementioned PCR buffer condi-
tions and thermal cycler temperature profile. The trp-2
1-472-cA fusion gene was gel purified as described previ-
ously. The pcDNA: trp-2 1-472-cA expression plasmid was
constructed by ligating HindIII and NotI digested trp-2
1-472-cA fusion gene with HindIII and NotI digested
pcDNA 3.1 His B (Invitrogen, USA). Ligated plasmid
product was heat-transformed into E. coli TOP10
(Invitrogen, USA) cloning host.
CHO-S cells maintenance
Suspension-adapted FreeStyle™ CHO-S cells (Invitrogen,
USA) were routinely cultured in 30 ml of 8 mM L-glu-
tamine supplemented FreeStyle™ CHO Expression
Medium (Invitrogen, USA) at densities of 1.2–1.5 ×
106 cell/ml using disposable Erlenmeyer tissue culture
flasks with vented caps (Thermo-Scientific, USA) and
shaken at 125–135 rpm on orbital shakers placed in
an incubator (37 °C, 8 % CO2). Cell viability and con-
fluency were monitored by manual haemocytometer
assisted cell counting which confirmed 98 % non-
aggregating cell viability during cell maintenance under
the described condition.
Plasmid DNA transfection into CHO-S cells
Large scale plasmid extraction was carried out by using
QIAGEN ® Plasmid Maxi Kit (QIAGEN, USA) in order
to obtain a concentrated (~1 mg/mL) target pcDNA:
trp-2 1-472-cA expression plasmid for transfection. Cells
were sub-cultured with fresh medium at 0.5–0.6 × 106
cells/ml density a day prior to transfection, in order to
obtain 1–1.5 × 106 cells/ml confluency for transfection.
The cell density was adjusted at 1 × 106cells/ml and
the culture medium was replaced with fresh culture
medium. A total 480 ml culture was transfected by
separately transfecting 16 replicates of 30 ml cell cul-
ture in 125 ml Erlenmeyer tissue culture flasks per
constructed plasmids. The transfection was carried
out by diluting 37.5 μl of FreeStyle™MAX reagent
(Invitrogen, USA) and 37.5 μg plasmid DNA separately
into 0.6 ml of Opti-PRO™ Serum Free Medium, SFM
(Invitrogen, USA), and then the two solutions weremixed
together. The resulting 1.2 ml DNA-FreeStyle™MAX
reagent mixture was incubated at room temperature
for 10 min. The mixture was then added drop wise
into 1 × 106 cells/ml cell suspension while gently
swirling the flask and transfected cells were subse-
quently shaken at 135 rpm for three days in a CO2
incubator at 37 °C. Cells were harvested on the third
day post-transfection for protein analysis by SDS-PAGE
and Western Blot.
Protein expression
Approximately 0.3 g in wet weight of pcDNA: trp-21-472-cA
transfected CHO-S cells and wild type CHO-S cells were
resuspended in 1 mL of 20 mM of sodium phosphate buf-
fer, pH 7.5 before being sonicated respectively in ice for
5 min with 50 % pulse at maximum microctip sonication
power. The cell lysate was clarified by centrifugation at 10
000 × g for 10 min in 4 °C. The supernatant was collected
for both TRP-224-472-cA fusion protein expression and its
subsequent PNGase deglycosylation analysis via Western
blot. The supernatant fraction of both transfected and wild
type CHO-S cell were also used for the following TRP-2
subunit enzymatic assay.
PNGase deglycosylation analysis
The glycosylation status of TRP-2-cA fusion protein was
determined by PNGase F (New England Biolabs, USA)
deglycosylation assay. Briefly, 9 μl of crude transfected
CHO-S cell lysate (~2.0 mg/ml) was mixed with 1 μl of
Glycoprotein Denaturing Buffer and boiled at 100 °C for
10 min. Then, 2 μl of GlycoBuffer 2 and 10 % NP40
were added to the denatured protein mixture together
with 1 μl of PNGase F enzyme. Appropriate amount of
distilled water was added to obtain a final reaction
volume of 25 μl. The reaction tubes were incubated
at 37 °C for 2 h or 12 h. The PNGase F deglycosylated
crude TRP-2-cA fusion protein was analysed compara-
tively to the untreated control by Western Blot.
Dopachrome tautomerization assay
The melanogenic activity of the TRP-2 subunit within
the TRP-21-472-cA fusion protein was tested through
dopachrome tautomerization assay as described by
Aroca et al., [32]. The substrate, L- dopachrome was
prepared by mixing 160 μl of 0.6 mM of L-DOPA
(Acros, USA) in 10 mM sodium phosphate buffer,
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pH 6.0 with 40 μl of 4.8 mM of sodium periodate
(Acros, USA) which was also dissolved in the same buf-
fer. The mixture was then diluted with 700 μl of 10 mM
sodium phosphate buffer, pH 6.0 yielding 0.1 mM of L-
dopachrome. A volume of 150 μl of 0.1 mM L-dopa-
chrome was mixed with 50 μl of transfected and wild
type CHO-S cell lysates respectively by triplicate wells of
ELISA plates (Nunc™ MicroWell™ 96 Well Microplates,
Thermo Scientific, USA). The ELISA plate was then in-
cubated at 30 °C. Absorbance at 475 nm for both control
and experiment reaction fractions were recorded for
each 5 min interval for 20 min.
TRP-224-472-cA fusion protein purification
The TRP-224-472-cA fusion protein was purified by using
His-tag affinity chromatography. A total of ~6.0 g in wet
weight of CHO-S cells was suspended in 20 mM phos-
phate buffer (pH 7.5) with 1 mM PMSF. The cells suspen-
sion was divided into aliquots, and each aliquot was
sonicated in ice for 5 min with 50 % pulse at maximum
microctip sonication power. Once sonicated, cells aliquots
were pooled together and incubated in ice for an hour.
The lysate was clarified by centrifugation at 20, 000 x g for
45 min and the resulting supernatant was filter sterilized.
An appropriate amount of glycerol was added to the crude
supernatant which ultimately resulted in ~55 ml of
20 mM sodium phosphate buffer (pH 7.5) with 5 % gly-
cerol (Buffer A) crude supernatant suspension.
Affinity chromatography was conducted by using 1 ml
HisTrap HP (GE Healthcare, USA) for Ni-NTA His tag
purification at pH 7.5. The column was equilibrated with
Buffer A before crude protein supernatant was applied
to the column. The column was then washed using
washing buffers; 20 mM sodium phosphate buffer
pH 7.5 with 40 mM of imidazole. The bound fraction
was eluted with 20 mM phosphate buffer pH 7.5 with
250 mM imidazole.
Protein anchoring
Protein anchoring to the L.lactis cell wall was conducted
similar to the previously described in-trans surface dis-
play report [31]. Overnight L.lactis MG1363 culture
grown in M17 broth [33] was subcultured into fresh
M17 broth and grown until cell density OD600, reaches
0.5 or 0.6. A volume of 100 μl of cells from this sus-
pension was harvested and resuspended in 100 μl of
1 × PBS. Approximately 30 μg of target or control
proteins and 300 μl of M17 broth were added to the
cell mixture. The cell-protein suspension was incu-
bated at 30 °C with gentle shaking (70–90 rpm) for
2 h. The cell-protein suspension was centrifuged and
the cell pellet washed thrice with 1 × PBS. The final
washed cell pellet was resuspended in 200 μl of 1 × PBS
for immunofluorescence microscopy analysis.
Immunofluorescence microscopy analysis
Cell wall anchoring status was determined by immuno-
fluorescence microscopy based on fluorescence conju-
gated secondary antibody tagging. The Teflon Coated
Immunofluorescence Slide (Polysciences, USA) 6 mm
well was treated with 0.01 % of Poly-L-Lysine solution
(Sigma-Aldrich, USA) and washed thrice with 1 × PBS.
A volume of 50 μl L.lactis cells (~1 × 104 cells) was fixed
on the slide well and incubated at room temperature for
30 min followed by 1 × PBS washing. Cells were then
coated with 4 % paraformaldehyde and incubated at
room temperature for 20 min before being washed three
times with 1 × PBS. The cells were blocked for 30 min
with 3 % BSA blocking solution and washed three times
with 1 × PBS. The fixed cells were incubated with Anti-
TRP2 Rabbit Polyclonal Antibody ab74073 (Abcam,
USA) (0.2 μg/μl) in 1 % BSA (dissolved in 1 × PBS), for
1 h at room temperature. The cells were then washed
thrice with 1 × PBS and incubated for 1 h at room
temperature with Alexa Flour ® 488 goat anti-rabbit
Antibody (Molecular Probes ®, USA) (2 μg/μl) prepared
by 1:200 dilution in 1 % BSA (dissolved in 1 × PBS).
Cells were subsequently washed thrice with 1 × PBS and
subjected to 4’,6-Diamidino-2-phenylindole, DAPI nu-
cleic acid staining by incubating with 0.5 μg/ml DAPI,
Dihydrochloride (Calbiochem, USA) for 30 min. Post
1 × PBS washing, cells were then coated with 10 μl of
Flourguard Antifade Mounting Solution (Sigma-Aldrich,
USA).
The method was also repeated with cells which
interacted with cA protein (obtained from Microbial
Biotechnology Laboratory, Faculty of Biotechnology
and Biomolecular Science, UPM) as positive control
using Anti His∙Tag® Monoclonal (Novagen, USA) pri-
mary antibody and Goat Anti-Mouse Flourescein
Conjugated (Calbiochem, USA) secondary antibody.
For a negative control, cells were mixed with 30 μg
of wild type CHO-S cell crude intracellular protein in
1 × PBS using the same method described earlier.
Results
Plasmid construction
In this study the mammalian expression plasmid har-
bouring a trp1-472-cA fusion gene, pcDNA: trp1-472-cA
was constructed. The heterologous gene was codon opti-
mised, synthesized and cloned into pcDNA 3.1 His B
(Invitrogen, USA). The native murine TRP-2 signal pep-
tide was replaced with the Chinese Hamster TRP-2 sig-
nal peptide as well as six histidine repeats and an
enterokinase site was included at the 3’-end of the fusion
gene. These modifications were carried out to aid target
glycoprotein production in CHO-S cells and its subse-
quent purification. The resulting plasmid and heterol-
ogous fusion gene is described in Fig. 1.
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Production & purification of TRP-224-472-cA fusion
glycoprotein
The production of TRP-224-472-cA fusion glycoprotein
by pcDNA: trp1-472-cA transfected CHO-S cells was ana-
lysed by SDS-PAGE and Western Blotting. Based on the
Western Blot, the harvested crude protein supernatant
showed TRP-224-472-cA as a specific band detected
at ~ 90 kDa (Fig. 2). Since the predicted molecular weight
with the absence of glycosylation for TRP-224-472-cA fu-
sion protein was ~ 74 kDa, the detection of a specific band
with an excess of ~16 kDa was a preliminary indicator of
potential glycan moieties present in the target protein.
This was confirmed by PNGase F digestion which resulted
in significant reduction in TRP-224-472-cA protein mo-
lecular weight from ~90 kDa to ~70 kDa after diges-
tion (Fig. 2). Subsequently, the bio-functionality of the
TRP-2 subunit in the target fusion protein was analysed
through its ability to catalyse dopachrome tautomeriza-
tion. The distinct decolorization of the L-dopachrome
substrate (reduction in A475 nm) was observed after
20 min incubation at 30 °C in the crude protein
fraction containing TRP-224-472-cA fusion protein-
substrate mixture, in contrast to wild-type CHO-S
cell crude protein-substrate mixture (Table 1). This
indicates that the TRP-2 subunit in fusion glycopro-
tein is enzymatically active.
Fig. 1 Schematic diagram of pcDNA:trp-21-472-cA
Fig. 2 Deglycosylation of TRP-224-472-cA fusion protein by PNGase treatment. Lane M: PageRuler™ Prestained Plus Protein Ladder (Fermentas, Canada);
Lane 1 : Undigested TRP-224-472-cA fusion protein; Lane 2: Replicate of undigested TRP-224-472 -cA fusion protein Lane 3: PNGase digested TRP-224-472-
cA fusion protein; Lane 4: Replicate of PNGase digested TRP-224-472-cA fusion protein
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The crude supernatant harvested from ~6.0 g of cells
(wet weight) was subjected to His- tag affinity chroma-
tography. Western blot analysis of the eluted fraction
resulted in ~90 kDa target protein eluted at 250 mM
imidazole (Fig. 3).
Immunofluorescence microscopy analysis
Cell wall anchoring of glycosylated target protein,
TRP-224-472-cA was analysed to determine the bio-
functionality of cA, the cell wall anchoring LysM
motif. It was observed that the L. lactis MG1363 cells
treated with TRP-224-472-cA and cA protein alone
(positive control for immunofluorescence microscopy)
respectively, emitted green fluorescence signals in
contrast to those treated with the negative control
(L.lactis treated with wild-type CHO-S crude protein
in 1 × PBS) (Fig. 4). This confirmed that the target
glycoprotein, TRP-224-472-cA, was anchored to the cell
wall of L. lactis MG1363. In order to determine if the
location of the target glycoprotein correlated with the
presence of the L. lactis, DAPI staining was per-
formed. As shown in Fig. 4, TRP-224-472-cA glycopro-
tein co-localized with L. lactis. Therefore, the target
TRP-224-472-cA glycoprotein was expressed in-trans by
L. lactis cells through the successful anchoring of the
target to its cell wall.
Discussion
In this work, an in-trans surface display system was
utilized to generate L. lactis surface displaying the
mammalian glycoprotein TRP-2. A vaccine using non-
recombinant prokaryotes to deliver glycosylated eukaryotic
proteins, is an attractive one, especially due to the
low cost involved in generating sufficient quantities
for the delivery system. Hitherto, bacterial in-trans and re-
combinant surface display of heterologous proteins were
very much associated with non-glycosylated protein pro-
duced by prokaryotic cell factories. Such an approach is
Table 1 OD475nm absorbance reading of L-dopachrome respectively mixed with wild-type CHO-S and transfected CHO-S crude
protein
Sample Wild type CHO-S crude protein extract pcDNA: trp-21-472-cA transfected CHO-S cell crude protein extract
Replicates 1 2 3 1 2 3
0 min 0.203 0.205 0.202 0.205 0.208 0.206
5 mins 0.196 0.199 0.194 0.173 0.179 0.175
10 mins 0.184 0.188 0.180 0.140 0.147 0.143
15 mins 0.179 0.182 0.176 0.101 0.106 0.104
20 mins 0.170 0.173 0.168 0.093 0.098 0.095
Fig. 3 Purification of TRP-224-472-cA by His-tag affinity chromatography. a SDS-PAGE profile; (b) Anti-His Western Blot profile. Lane M: PageRuler™
Prestained Plus Protein Ladder (Fermentas, Canada); Lane 1: His-tag affinity chromatography unbound fraction; Lane 2: His-tag affinity chromatography
250 mM imidazole eluted fraction
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not suitable when the target protein requires post-
translational modifications for protein folding and bio-
functionality.
L. lactis surface display applications have been pre-
dominantly involved in antigen or epitopes delivery for
mucosal immunization through the oral route. This con-
cept was first demonstrated in the streptococcal system
by fusing the E7 protein of human papillomavirus type
16 with the C-terminal attachment motif of fibrillar M6
protein from Streptococcus pyogenes [34]. Since then, a
similar strategy has been extensively manipulated in the
lactococcal system by initially using sortase mediated cell
wall anchoring motifs such as, LPXTG casein serine
protein from L. lactis PrtP protein [35], S. pyogenes M6
protein [36] and Staphylococcus aureus protein A (SPA)
anchor [37]. The non-covalent cell wall binding domain,
cA (LysM-AcmA) domain, was compared with LPXTG
motifs, i.e. PrtP using recombinant technology in surface
displaying F18 Fimbrial Adhesin FedF, and was con-
cluded to be more efficient [28].
Despite successful heterologous protein surface display
for vaccine delivery by L.lactis through the nisin con-
trolled gene expression system (NICE®), genetic modifi-
cation of bacteria has been a safety concern. The GRAS
status of L. lactis and many other LABs is insignificant
as genetically modified microorganisms pose a risk of
horizontal gene transfer, particularly antibiotic resistance
gene transfer, in human and animal applications [10].
Fig. 4 Immunoflouroscence microscopy of L.lactis interacted with the TRP-224-472-cA glycoprotein. (i) DAPI nucleus staining for L. lactis cells (ii)
FITC conjugated Secondary Antibody Staining. a L. lactis interacted with cA protein (expressed and purified E.coli), (b) L. lactis interacted with wild
type CHO-S cells crude intracellular protein in 1 x PBS, (c) L. lactis interacted with TRP-224-472-cA glycoprotein
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These challenges can be overcome by the in-trans sur-
face display strategy which involves external cell wall
binding of target protein –LysM (AcmA) fusion proteins
produced from a host separate from the protein carrier.
Such fusion proteins have been successfully produced in
L. lactis [38], E.coli [9] and Pichia pastoris [39] before
being purified and anchored to LAB peptidoglycan. The
AcmA cell wall anchor also been used to bind recombinant
proteins to killed L. lactis termed Gram-positive Enhancer
Matrix (GEM) cells [40] as this system increases protein
binding by removing hindering cell wall compartments and
improves the biosafety of non-recombinant L. lactis vaccine.
Recently, N-glycosylation has been identified to signifi-
cantly enhance epitope presentation of MHC class I
molecules as demonstrated by using tyrosinase as a
model antigen [41]. This is due to de-glycosylation by
peptide N-glycanase (PNGase) during the glycosylation
process in the ER which allows deamidation for epitope
presentation. Apart from that, proteolysis for epitope
presentation was also discovered to slow down near the
N-glycan site thus resulting in the generation of native
epitopes [42]. Previously however, the surface display
strategy for glycosylated proteins has been restricted to
yeast [43], but this system compromises the quality of
the target glycoprotein, since yeast attach a different
linkage of carbohydrate moieties (primarily mannose) to
the core glycosyl unit and the system is highly suscep-
tible to hyperglycosylation. Due to these differences,
there is a preference for utilizing mammalian cells over
yeast in generating therapeutic glycoproteins [44, 45].
The present study addresses these problems by utilizing
the in-trans surface display system for glycoprotein de-
livery. In this study, TRP-2 glycoprotein fused with L.
lactis N-acetylmuramidase C-terminal LysM cell wall
anchor, cA, was expressed in a mammalian cell (CHO-S
cells) and subsequently anchored to the L. lactis cell
wall. This study demonstrates that glycosylated antigens
can be produced in a mammalian cell system and then
can be anchored to a bacterial cell surface, by fusion
with a cell wall anchoring motif such as cA.
Previously, most reported peptide based TRP-2 vac-
cines utilized highly antigenic short synthetic peptides
(epitopes) i.e. TRP-2180-188 [46, 47], chiefly due to the
difficulties in purifying the full length TRP-2 [32, 48].
Such an approach compromises the full length glycosyl-
ated TRP-2 immunogenic potential. Hitherto, high pur-
ity TRP-2 glycoprotein was successfully obtained from
Sf9 insect cells but only upon the removal of the hydro-
phobic C-terminal transmembrane domain [48].
In this study, TRP-2 devoid of the transmembrane
domain(TRP-224-472) was utilized to generate recombin-
ant protein. In addition, in order to promote TRP-2 gly-
cosylation and signal peptide recognition in the CHO-S
cell expression system, the murine TRP-2 signal peptide,
mTRP-2sp was substituted with Chinese Hamster TRP-2
maturation signal peptide, chTRP-2sp. Despite 91 %
amino acid sequence similarity between Chinese Ham-
ster TRP-2 and murine TRP-2, the signal peptidase
cleavage sequence varies considerably and the murine
version was unable to promote proper localization in the
CHO-S system (data not shown). Production of soluble
TRP-224-472-cA by CHO-S cells enabled His-tag purifica-
tion which resulted in the production of “partially puri-
fied” TRP-224-472-cA from recombinant CHO-S cells.
Even though purity was poor, this method resulted in a
protein fraction with enriched target protein.
The final phase of this study was to analyse the
ability of TRP-224-472-cA glycoprotein to anchor onto
the L. lactis cell wall. This assay was first demon-
strated by Steen et al., [38] by interacting 15 μg of
cA protein expressed and purified from L. lactis
NZ9700 with trichloroacetic acid-treated L. lactis. Since
then, the in-trans approach has been applied to externally
introduced target protein expressed and purified from
E. coli [9, 30, 31] to the L. lactis’ cell wall. Similarly,
the successful expression and purification of TRP-224-
472-cA fusion glycoprotein from CHO-S cells in this
study generated a novel TRP-2 glycoprotein with L.
lactis cell wall anchoring properties. The cA domain
cell wall anchoring feature was confirmed by
visualization of TRP-224-472-cA glycoprotein mixture
with live L. lactis through immunofluorescence mi-
croscopy (Fig. 4). The functionality of prokaryotic (L.
lactis) cell wall anchoring domain, cA expressed and
purified from eukaryotes has been previously demon-
strated [39]. The aforementioned study successfully
docked yeast produced cA, which was mutated to
eliminate N-glycosylation sites thought to possibly
hinder docking, onto the cell surface of Lactobacillus
casei NRRL B-441 [39]. Despite none of the predicted
N-glycosylation sites present in the cA domain were
eliminated in this study, the anchoring motif was
shown to be fully functional and capable of anchoring
glycosylated TRP-2 onto the L. lactis’ cell wall.
While the concept of surface displaying glycosylated
eukaryotic proteins on prokaryotic bacteria using the
above approach was proven successful, the major
drawback has been the initial low expression of the tar-
get fusion protein produced by the transient CHO-S ex-
pression system. This restriction has accounted for
difficulties in accumulating sufficient amount of the pure
target proteins, limiting the study to the characterization
of the glycosylation of the TRP-224-472-cA fusion protein
and immunogenicity analysis using in vivo models.
Optimization of the current transient expression system
or development of a stable cell line expressing the
TRP-224-472-cA fusion protein will have to be carried
out before the system can be fully utilized.
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Conclusion
In summary, this study represents a novel method of
displaying eukaryotic proteins on bacterial carriers such
as L. lactis when post-translational glycosylation is cru-
cial for functionality. The system developed in this study,
i.e. L. lactis surface displaying TRP-2, is anticipated to be
able to function as a cancer vaccine which will be inves-
tigated in future studies once sufficient target protein
production is achieved. The vaccine which could be ad-
ministered orally or intranasally, would likely to induce
an antigen specific immune response against glioma and
melanoma cells, triggering immune effectors including
antigen specific CD8+ cells and antibodies as has
been detected in other studies utilizing LAB as antigen
carriers.
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